Proactive Investors - Run By Investors For Investors

Neurotrope candidate in bid to treat Alzheimer's

Neurotrope revealed first patients have been dosed in its phase 2b clinical trial of lead candidate Bryostatin-1 for advanced Alzheimer’s disease.
Neurotrope candidate in bid to treat Alzheimer's
Charles S. Ramat, Neurotrope president and chief executive, told investors: "We believe that Bryostatin represents a new and disruptive technology in what has been an unsuccessful war against Alzheimer’s disease."
Neurotrope (OTCMKTS:NTRP) revealed first patients have been dosed in its phase 2b clinical trial of lead candidate Bryostatin-1 for advanced Alzheimer’s disease.
 
The company expects to report three month interim data during the first quarter of 2017 with complete six month data set expected during the first half of 2017.
 
Charles S. Ramat, Neurotrope president and chief executive, told investors: "We believe that Bryostatin represents a new and disruptive technology in what has been an unsuccessful war against Alzheimer’s disease. 
 
"This trial seeks to statistically verify preliminary results seen in compassionate use patients and patients treated in our completed Phase 2a study,” 
 
 “We are excited at being on the cusp of providing a meaningful treatment to this suffering, severely impaired population and their caregivers.”
 
The Bryostatin-1 Phase 2b trial is an ongoing randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability and efficacy of the drug in the treatment of patients suffering from moderately severe to severe Alzheimer’s.
 
The study plans to enroll 150 patients at 30 US sites. 
 
It will evaluate two different doses of Bryostatin (20 or 40µg) versus placebo, with a total of seven doses administered over 12 weeks. 
 
A second randomization will take place after the first 12 weeks of treatment, with patients in the Bryostatin arms to receive either a different dose of Bryostatin or the same dose. 
 
Patients in the placebo arm will be randomized to receive either Bryostatin (10µg) or placebo.
 
Shares added 2.5%..
View full NTRP profile View Profile

Neurotrope Timeline

Related Articles

Challenge trials can speed up vaccine development
May 30 2019
The challenge trial charts the entire disease life cycle from healthy to sick and back to health.
1538160791_petri-dishes.jpg
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
Surgery
February 20 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use